清咳平喘颗粒对COPD急性加重期的临床疗效

doi:10.11958/20231914

摘要/Abstract

摘要：

目的探讨清咳平喘颗粒对慢性阻塞性肺疾病急性加重期（AECOPD）患者临床疗效的影响。方法选取80例呼吸科住院治疗的AECOPD患者，其中常规组和联合组各40例，分别于治疗前、治疗第2周末、治疗1个月后观察2组患者自我评估测试（CAT）评分、疗效指数、白细胞介素（IL）-6水平、C-反应蛋白（CRP）水平、第1秒用力呼气容积（FEV1）/用力肺活量（FVC）、FEV1占预计值百分比（FEV1%pred）的差异。结果联合组总有效率高于常规组（92.5% vs. 75.0%，P<0.05）。治疗第2周末，2组FEV1%pred、FEV1/FVC、IL-6水平、CRP水平与治疗前比较均有所改善，且联合组改善程度优于常规组（P<0.05），2组患者呼吸衰竭比例均较治疗前明显好转；随访1个月，联合组CAT评分回弹率低于常规组（P<0.05）；2组不良反应发生率差异无统计学意义（12.5% vs. 2.5%，P>0.05）。结论清咳平喘颗粒能有效改善AECOPD患者的临床症状及肺功能，提高生活质量。

关键词: 肺疾病，慢性阻塞性, 痰浊阻肺, 中西医结合疗法, 清咳平喘颗粒

Abstract:

Objective To study the effect of Qingke Pingchuan Granule on the clinical efficacy in patients with phlegm-heat obstructing lung syndrome (AECOPD). Methods A total of 80 patients with acute exacerbation of chronic obstructive pulmonary disease (syndrome of phlegm-heat stagnation in the lung) hospitalized in the respiratory department of our hospital were selected and divided into the conventional group and the combinational group, with 40 cases in each group. The CAT score, TCM syndrome score, serum IL-6, CRP, lung function FEV1%pred, and FEV1/FVC were retrospectively observed before treatment, at the end of the second week of treatment, and at the follow-up after 1 month of treatment in the two groups. Results The total effective rate was significantly better in the combinational group than that of the conventional group (92.5% vs. 75.0%，P<0.05). At the end of the second week of treatment, the CAT score, each single syndrome score, serum IL-6 and CRP levels were all improved than those before treatment in the two groups (P<0.05), and the improvement degree was better in the combined group than that of the conventional group (P<0.05). The severity of airflow limitation and respiratory failure were significantly improved compared with those before treatment in both groups. At the follow-up after 1 month of treatment, the recovery rate of scores of each single syndrome score and CAT score were significantly lower in the combined group than those in the routine group (P<0.05). There were no significant differences in adverse drug reactions between the two groups (12.5% and 2.5%, P>0.05). Conclusion Qingke Pingchuan Granule can effectively relieve the symptoms and improve lung function and the quality of life of AECOPD patients.

Key words: pulmonary disease, chronic obstructive, turbid phlegm obstructing lung, integrated chinese traditional and western medicine therapy, Qingke Pingchuan Granule

中图分类号:

R563.9

图/表 5

参考文献 11

[1]	ZHOU M, WANG H, ZENG X, et al. Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. doi:10.1016/S0140-6736(19)30427-1.
[2]	《中成药治疗优势病种临床应用指南》标准化项目组. 中成药治疗慢性阻塞性肺疾病临床应用指南(2021年)[J]. 中国中西医结合杂志, 2022, 42(8):901-914.
	Standardization project group of Clinical Application Guidelines for the Treatment of Dominant Diseases with Chinese Patent Medicine. Clinical application guidelines for the treatment of chronic obstructive pulmonary disease with Chinese patent medicine(2021)[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2022, 42(8):901-914. doi:10.7661/j.cjim.20220413.045.
[3]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3):170-205.
	COPD Group of Respiratory Society of Chinese Medical Association,COPD Working Committee of Chinese Association of Respiratory Physicians. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(3):170-205. doi:10.3760/cma.j.cn112147-20210109-00031.
[4]	李建生, 李素云, 余学庆. 慢性阻塞性肺疾病中医诊疗指南(2011版)[J]. 中医杂志, 2012, 53(1):80-84.
	LI J S, LI S Y, YU X Q. Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (version 2011)[J]. Journal of Traditional Chinese Medicine, 2012, 53(1):80-84. doi:10.13288/j.11-2166/r.2012.01.011.
[5]	JONES P W, HARDING G, BERRY P, et al. Development and first validation of the COPD assessment test[J]. Eur Respir J, 2009, 34(3):648-654. doi:10.1183/09031936.00102509.
[6]	世界中医药学会联合会. 国际中医临床实践指南慢性阻塞性肺疾病[J]. 世界中医药, 2020, 15(7):1084-1092.
	World Federation of Chinese Medicine Societies. International Clinical Practice Guideline of Chinese Medicine Chronic Obstructive Pulmonary Disease[J]. World Chinese Medicine, 2020, 15(7):1084-1092. doi:10.3969/j.issn.1673-7202.2020.07.026.
[7]	王蕾, 杨涛, 李曼, 等. 黄芪甲苷预处理对大鼠肠缺血再灌注所致肺损伤的影响及其机制[J]. 中国中西医结合外科杂志, 2023, 29(1):99-102.
	WANG L, YANG T, LI M, et al. Effects of astragaloside Ⅳ pre-treatment on lung injury induced by intestinal ischemia-reperfusion in rats[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine Surgery, 2023, 29(1):99-102. doi:10.3969/j.issn.1007-6948.2023.01.020.
[8]	MCDONOUGH J E, YUAN R, SUZUKI M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease[J]. N Engl J Med, 2011, 365(17):1567-1575. doi:10.1056/NEJMoa1106955.
[9]	DE CUNTO G, CAVARRA E, BARTALESI B, et al. Innate immunity and cell surface receptors in the pathogenesis of COPD: insights from mouse smoking models[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15:1143-1154. doi:10.2147/COPD.S246219.
[10]	DI T, YANG Y, FU C, et al. Let-7 mediated airway remodelling in chronic obstructive pulmonary disease via the regulation of IL-6[J]. Eur J Clin Invest, 2021, 51(4):e13425. doi:10.1111/eci.13425.
[11]	蔡珍珍, 彭建平, 黄建华, 等. 清咳平喘颗粒联合西医常规治疗慢性阻塞性肺疾病急性加重期患者的临床疗效观察[J]. 中草药, 2023, 54(14):4584-4589.
	CAI Z Z, PENG J P, HUANG J H, et al. Clinical observation of Qingke Pingchuan Granules combined with conventional western medicine in treatment of acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Traditional and Herbal Drugs, 2023, 54(14):4584-4589. doi:10.7501/j.issn.0253-2670.2023.14.019.

组别	性别（男/女）	年龄/岁	COPD病程/年	急性期病程/d
常规组	28/12	64.23±6.36	7.50（4.25，10.75）	2.25（4.00，6.00）
联合组	25/15	63.63±6.94	7.00（4.25，10.00）	3.00（2.00，6.00）
χ²、t或Z	0.503	0.403	0.333	0.335

组别	性别（男/女）	年龄/岁	COPD病程/年	急性期病程/d
常规组	28/12	64.23±6.36	7.50（4.25，10.75）	2.25（4.00，6.00）
联合组	25/15	63.63±6.94	7.00（4.25，10.00）	3.00（2.00，6.00）
χ²、t或Z	0.503	0.403	0.333	0.335

组别		FEV1%pred/%
组别		治疗前					治疗第2周末				t₂
常规组		56.81±12.84					62.95±13.45				17.816^＊
联合组		57.41±12.40					70.09±14.21				20.431^＊
t₁		0.200					2.522^＊
组别			FEV1/FVC/%
组别			治疗前			治疗第2周末				t₂
常规组			53.32±5.51			55.87±5.60				12.330^＊
联合组			53.91±5.66			57.12±5.84				16.244^＊
t₁			0.437			2.898^＊
组别	呼吸衰竭							GOLD分级（1—2级/3—4级）
组别	治疗前			治疗第2周末	χ²			治疗前	治疗第2周末			χ²
常规组	29（72.5）			3（7.5）	24.038^＊			25/15	28/12			0.503
联合组	31（77.5）			6（15.0）	23.040^＊			23/17	30/10			2.739
χ²	0.267			1.127				0.208	0.251

组别		FEV1%pred/%
组别		治疗前					治疗第2周末				t₂
常规组		56.81±12.84					62.95±13.45				17.816^＊
联合组		57.41±12.40					70.09±14.21				20.431^＊
t₁		0.200					2.522^＊
组别			FEV1/FVC/%
组别			治疗前			治疗第2周末				t₂
常规组			53.32±5.51			55.87±5.60				12.330^＊
联合组			53.91±5.66			57.12±5.84				16.244^＊
t₁			0.437			2.898^＊
组别	呼吸衰竭							GOLD分级（1—2级/3—4级）
组别	治疗前			治疗第2周末	χ²			治疗前	治疗第2周末			χ²
常规组	29（72.5）			3（7.5）	24.038^＊			25/15	28/12			0.503
联合组	31（77.5）			6（15.0）	23.040^＊			23/17	30/10			2.739
χ²	0.267			1.127				0.208	0.251

组别	治疗前/分	治疗第2周末/分	随访1个月/分	评分回弹率/%
常规组	29.20±4.31	19.10±3.64	23.88±4.13	25.94±11.96
联合组	30.05±4.24	17.50±2.74	20.18±3.49	15.49±12.09
t	0.890	2.221^＊	4.332^＊	3.884^＊